Orchestra BioMed
OBIO
63 hedge funds and large institutions have $90.1M invested in Orchestra BioMed in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 5 closing their positions.
333% more call options, than puts
Call options by funds: $329K | Put options by funds: $76K
320% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 5
61% more capital invested
Capital invested by funds: $56.1M → $90.1M (+$34M)
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
21% more funds holding
Funds holding: 52 → 63 (+11)
3.99% less ownership
Funds ownership: 42.42% → 38.43% (-4%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$823K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$693K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$653K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$495K |
| 5 |
Goldman Sachs
New York
|
+$446K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pathstone Holdings
Englewood,
New Jersey
|
-$2.49M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.47M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$955K |
| 4 |
Renaissance Technologies
New York
|
-$925K |
| 5 |
PA
Perceptive Advisors
New York
|
-$667K |
OBIO Hedge Fund Activity: Q4 2025 in Review
63 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2025, worth a combined $90.1M — up 61% from $56.1M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new OBIO positions and 5 closed out — a net gain of 16 holders — while 17 added to existing stakes and 14 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $823K. The largest seller was Pathstone Holdings, exiting entirely with an estimated $2.49M sold.
- 63 institutional investors held Orchestra BioMed (OBIO) as of Q4 2025, up from 52 in Q3 2025.
- Funds reported $90.1M of Orchestra BioMed stock for Q4 2025, up 61% quarter-over-quarter.
- 21 funds opened new Orchestra BioMed positions in Q4 2025 and 5 closed out, a net change of +16 holders.
- The largest Orchestra BioMed buyer in Q4 2025 was 683 Capital Management, an estimated $823K added.
- The largest Orchestra BioMed seller in Q4 2025 was Pathstone Holdings, an estimated $2.49M sold.
Based on aggregated 13F filings for Q4 2025.